From the impact of Obamacare to cutting-edge research, biotech buyouts to FDA decisions, The Motley Fool's health-care team sits down each week to discuss the most fascinating developments in health care and their implications for long-term investors. In this week's edition, the team talks about The Atlantic's fifth annual Health Care Forum, biotechs in the news, two stocks investors need to watch, and more.
In the segment below, health-care analyst David Williamson explains why Dendreon needs to be on investors radars. It has seen wins for both its competitors, growing U.S. Zytiga sales and a big step toward European approval for Xtandi. With earnings coming this Thursday, May 9, watch and find out what investors should be paying attention to.
Resurgence or dead cat bounce?
Shares of Dendreon have surged in recent months, with the stock gaining new life from the depths of late 2012. Has the company really solved its underlying problems, or are investors setting themselves up for more disappointment? Our new premium research report on Dendreon answers these questions and many more while also outlining just how Dendreon intends to regain its former glory. Claim your copy by clicking here now.